High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non‐small cell lung cancer

BACKGROUND: The treatment efficacy of immune checkpoint inhibitor (ICI) and clinical outcomes in patients with non‐small cell lung cancer (NSCLC) who develop severe grade checkpoint inhibitor pneumonitis (CIP) are unclear. Here, we report on the treatment efficacy of ICI and prognosis in NSCLC patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Tone, Mari, Izumo, Takehiro, Awano, Nobuyasu, Kuse, Naoyuki, Inomata, Minoru, Jo, Tatsunori, Yoshimura, Hanako, Minami, Jonsu, Takada, Kohei, Miyamoto, Shingo, Kunitoh, Hideo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775002/
https://www.ncbi.nlm.nih.gov/pubmed/31482678
http://dx.doi.org/10.1111/1759-7714.13187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775002/
https://www.ncbi.nlm.nih.gov/pubmed/31482678
http://dx.doi.org/10.1111/1759-7714.13187

Ejemplares similares